VIVUS — Investor Presentation (January 2015)
33 slides from VIVUS's investor presentation, Jan 15, 2015
Slide 1: Innovative Therapies Novel Products
Innovative Therapies Novel Products January 2015 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 2: Forward looking statement
Forward looking statement This presentation contains "forward-looking" statements that involve risks and uncertainties. These statements typically may be identified by the use of forward-looking words or phrases such as "may," "believe," "expect," "forecast," "intend," "anticipate," "predict," "shou
Slide 3: VIVUS milestones - 2014
VIVUS milestones - 2014 Qsymia New clinical publications (CV benefit-risk; efficacy in high BMI patients; efficacy in older patients) New market access initiatives (pharmacoeconomic data; formulary positioning) New DTP-oriented initiatives; search engine optimization (SEO) New patents issued and oth
Slide 4: Obesity Market & Qsymia
Obesity Market & Qsymia 3 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 5: Over 110 million US adults are obese or overweight with a comorbidity
HTN: 20.0 M HTN2/ Dyslipidemia: 11.4 M HTN/Diabetes/ Dyslipidemia: 21.9 M Diabetes/ Dyslipidemia: 5.0 M Dyslipidemia: 35.0 M HTN/ Diabetes: 2.8 M Diabetes: 1.4 M U.S. Obese and Overweight w/co-morbidity population1 Over 110 million US adults are obese or overweight with a weight-related comorbidity
Slide 6: About Qsymia
About Qsymia Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related med
Slide 7: Qsymia magnitude of effect
Qsymia magnitude of effect Pivotal 1-Year Studies: Weight Loss Over Time (Observed/ITT Data) 6 Study 1 (EQUIP1) Study 2 (CONQUER2) Time (Week) Time (Week) 56 ITT-LOCF 56 ITT-LOCF All observed data; *p<0.0001 vs placebo; ‡p<0.0001 vs. Qsymia Mid or Low The most commonly observed side effects in contr
Slide 8: Qsymia consistency of effect
Qsymia consistency of effect 7 *Dvorak, R., Peterson, C., Day, W. Application of Proposed Treatment Algorithm (PTA) Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release Topiramate (PHEN/TPM ER) Presented at The Obesity Society 30th Annual Scientific Meeting, Sep-2012 - San Antonio;
Slide 9: Beneficial effects of weight loss with Qsymia
BENEFICIAL EFFECTS of WEIGHT LOSS WITH Qsymia 8 Diastolic BP Systolic BP Fibrinogen Triglycerides TChol:HDL IWQOL total Fasting glucose HOMA-IR Fasting insulin HbA1c hs-CRP ALT Apnea Hypopnea Index Placebo subtracted effect size Placebo subtracted effect size Favors Qsymia Favors Placebo Favors Qsym
Slide 10: Clinical Publications support the benefit-risk profile of Qsymia
Clinical Publications support the benefit-risk profile of Qsymia “Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release.” W. Timothy Garvey, MD, et al. Diabetes Care1 Patients on Recommended (7.5/46) and Top (15/92)
Slide 11: Obesity Treatment Evolution
Obesity Treatment Evolution 10 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 12: AACE Treatment algorithm: Medical Therapy is Recommended
AACE Treatment algorithm: Medical Therapy is Recommended 11 Obesity management and FDA-approved anti-obesity medications now recommended for: Prediabetes Diabetes Dyslipidemia Hypertension 1st ever inclusion of drug therapy in treatment algorithm Primary Care Physicians refer to AACE algorithm ©2015
Slide 13: Greater recognition of obesity as a disease, pharmacotherapy as a treatment option
Greater recognition of obesity as a disease, pharmacotherapy as a treatment option Obesity is now recognized as a disease by the leading medical association in the U.S. AMA recognition is important support for policy makers, healthcare providers and payors Additional recent publications support long
Slide 14: Qsymia Commercialization
Qsymia Commercialization 13 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 15: Healthcare provider targeting
Healthcare provider targeting Ongoing deployment optimization includes Prioritizing targets based on prescribing behavior and other factors Analyzing and redefining territories Reconfiguring and redeploying sales resources against highest value targets Core Message: Qsymia delivers 5X the weight los
Slide 16: Healthcare provider engagement
Healthcare provider engagement Ongoing education process (guidelines; clinical data) Focus for new starts on high-need patient (BMI>35) Provides an avenue for Qsymia trial and adoption Maintain Free Trial Offer (14 days of Starting Dose) Works as a two-week sample; lowers out-of-pocket $ for patient
Slide 17: Patient engagement
patient engagement Ongoing DTP Outreach and Dialog Lapsed patients Treatment failures Treatment naïve patients Emphasis on Communities of Patients 16 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 18: Qsymia monthly TRx volume remained steady since Oct-2013
Source: IMS (Monthly) Qsymia monthly TRx volume remained steady since Oct-2013; anti-obesity market trxs grew 17 ©2015 VIVUS Inc. All rights reserved www.vivus.com MAT (000) AO Market TRxs Branded AO TRx Nov-2012 7,993 276 Nov-2013 8,432 (+5.5%) 613 (+122%) Nov-2014 9,270 (+10%) 1,227 (+100%) 39.0 3
Slide 19: Qsymia experience since launch
~51,000 Prescribers ~300,000 Patients ~900,000 Prescriptions Source: VIVUS Data Warehouse (PR) Qsymia experience since launch (through nov-2014) ©2015 VIVUS Inc. All rights reserved www.vivus.com 18
Slide 20: Qsymia TRxs by specialty
Spec CARD ENDO NP/PA OB/GYN PCP SURG Avg Rx/MD 13.0 38.7 8.3 12.5 12.1 9.2 Source: VIVUS Data on File, includes MO+PR Retail Qsymia trxs by Specialty – YTD nov-2014 Endo is the leading specialty by productivity ©2015 VIVUS Inc. All rights reserved www.vivus.com 19 CARD 1% ENDO 5% NP/PA 18% OB/GYN 4%
Slide 21: Qsymia coverage is steady
Qsymia coverage is steady Q4 2013 2014 20 ©2015 VIVUS Inc. All rights reserved www.vivus.com 38% 38% 43% 43% 44% 44% 44% 46% 46% 48% 48% 48% 48% 48% % Access
Slide 22: Qsymia pharmacoeconomics supported in the literature
Qsymia pharmacoeconomics supported in the literature Finkelstein, E. A. and Kruger, E. (2014), Meta- and cost-effectiveness analysis of commercial weight loss strategies. Obesity, 22: 1942–1951. doi: 10.1002/oby.20824 Study conducted by researchers at Duke-National University of Singapore (NUS) Grad
Slide 23: Qsymia has exclusive formulary position with CVS/Caremark
Qsymia has exclusive formulary position with cvs/caremark Qsymia is the sole antiobesity agent listed on the CVS/Caremark Performance Drug List Preferred brand (Tier 2) that is clinically appropriate in an antiobesity class ©2015 VIVUS Inc. All rights reserved www.vivus.com 22
Slide 24: OPM Endorses use of Anti-Obesity Medications for Federal Employees
OPM Endorses use of Anti-Obesity Medications for Federal Employees (Mar-2014) OPM=Office of Personnel Management 23 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 25: Qsiva CVOT Qsymia IP
Qsiva CVOT Qsymia IP 24 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 26: Qsiva European strategy
Qsiva European strategy Goal Satisfy FDA post-approval requirements with a single CVOT (AQCLAIM/OB-401) that may also support EU registration Strategy Create interim analysis CVOT so that ~two years of data may be used to support an application while trial continues Tactics/Implementation Dialog ong
Slide 27: AQCLAIM study (CVOT)
Aqclaim study (CVOT) A Qsymia® CardiovascuLAr morbIdity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease Primary Efficacy Endpoint: Time to 1st occurrence of nonfatal MI, nonfatal stroke or CV death Number of Subjects: ~11,000 – 16,000 Number of Sites: ~450 (North Ame
Slide 28: New patents extend Qsymia coverage to 2029
New patents extend qsymia coverage to 2029; acquisition of additional patents removes uncertainty Four additional VIVUS patents with claims covering QSYMIA issued in 2013 and 2014, extending coverage by up to nine years U.S. Patent Nos. 8,580,298 and 8,895,058 26 and 32 claims, respectively, directe
Slide 29: Stendra Prescribing information
Stendra Prescribing information About STENDRA™ STENDRA is a prescription medicine used to treat erectile dysfunction (ED). STENDRA (avanafil) is licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS has development and commercial rights to STENDRA for the treatment of sexual dysfunction worldwid
Slide 30: Avanafil partnerships / update
avanafil partnerships / update Auxilium Pharmaceuticals, Inc. - U.S. & Canada U.S. launched 15-minute onset-of-action claim incorporated into STENDRA label (Sep-2014) Menarini - 40 Countries in Europe + AUS/NZ EU-5 launched; SPEDRA available in 23 countries within Menarini territory 15-minute onset-
Slide 31: Financial Update
Financial Update 30 ©2015 VIVUS Inc. All rights reserved www.vivus.com
Slide 32: VIVUS, Inc. cash and net revenue
VIVUS, Inc. Cash, Cash equivalents & Available-for-sale securities as of 30-Sep-2014: $306.9MM; as of 31-Dec-2013: $343.3MM ©2015 VIVUS Inc. All rights reserved www.vivus.com 31 YTD 30-Sep ($MM) 2014 2013 Net Revenue ($MM) Total Total Qsymia – Net product revenue $32.6 $16.0 STENDRA/SPEDRA – License
Slide 33: Innovative Therapies Novel Products
Innovative Therapies Novel Products January 2015 ©2015 VIVUS Inc. All rights reserved www.vivus.com